Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hinchey presses FDA

This article was originally published in The Tan Sheet

Executive Summary

Rep. Maurice Hinchey (D-N.Y.) will use an upcoming hearing on FDA's budget request to pose questions about conflicts of interest to Acting Commissioner Andrew von Eschenbach, Hinchey's office says. Von Eschenbach is scheduled to discuss FDA's budget request for fiscal 2007 at a Feb. 16 hearing held by the Appropriations Subcommittee on Agriculture, Rural Development, FDA & Related Agencies. Hinchey says his questions will center on "von Eschenbach's own conflict as NCI Director," FDA's recently restated policy of preemption and the agency's "cozy relationship" with the drug industry. The congressman has campaigned to prevent scientists and doctors with conflicts of interest from participating on FDA committees. In September, he requested that the HHS Office of the Inspector General review the resignation of former FDA Commissioner Lester Crawford (1"The Tan Sheet" Oct. 31, 2005, In Brief)...

You may also be interested in...

Crawford “review”

The HHS Office of the Inspector General is "reviewing the circumstances" surrounding the resignation of FDA Commissioner Lester Crawford in response to requests from members of Congress, IG Daniel Levinson confirmed in a recent letter to Rep. Maurice Hinchey (D-N.Y.) and colleagues. "Depending upon the results of the review, we will determine the next appropriate action," Levinson said. According to OIG staff, the review currently is not a formal investigation. Lawmakers called for the investigation in September (1"The Tan Sheet," Oct. 3, 2005, p. 4)...

Bharat Biotech Gets Shot In Arm With 81% Efficacy For COVID-19 Vaccine

Bharat Biotech’s COVID-19 vaccine has shown 80.6% efficacy in interim data from Phase III clinical trials, slightly better than the 79.3% reported by Sinopharm and significantly higher than Sinovac’s 50.6% for their vaccines based on similar technology. Supply deals are already on the way, with Brazil having signed up for 200 million doses.

Australia’s Manufacturing Road Map Wins Plaudits From Industry

A medicines manufacturing “road map” set out by Australia’s government has the backing of the local off-patent industry.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts